Memantine HCl ER Pellets

Product Overview

Memantine Hydrochloride ER Pellets are formulated for extended-release delivery, ensuring gradual and consistent absorption of Memantine HCl, an NMDA receptor antagonist used in the treatment of moderate to severe Alzheimer's disease. The extended-release pellet technology enables once-daily dosing, minimizes fluctuations in drug levels, and supports improved patient compliance and therapeutic outcomes. These pellets are produced using advanced polymer-coating techniques for precise and controlled drug release over a 24-hour period.

Product Name
Memantine HCl ER Pellets
Strengths Available
14% - 16% (customizable as per formulation needs)
CAS No. / IUPAC Name
CAS: 41100-52-1; IUPAC: 1-amino-3,5-dimethyladamantane hydrochloride
Molecular Formula / Weight
C₁₂H₂₁N · HCl/ ~215.76 g/mol
Identification
Validated HPLC Method (USP/BP/EP compliant)
Release Type
Extended Release (ER): Polymer-coated pellets designed for once-daily dosing with a 24-hour controlled release profile
Applications
Suitable for use in oral extended-release formulations such as hard gelatin capsules or sachets Indicated for the treatment of Alzheimer’s disease and related cognitive disorders
Storage Conditions
Store in a well-closed container in a cool, dry place, protected from light and moisture

Acetaminophen DC Granules – Typical Composition

Component	Function
Memantine Hydrochloride	Active Pharmaceutical Ingredient (API)
Sugar Spheres / MCC Spheres	Inert core / Neutral starter spheres for pellet formation
Hydroxypropyl Methylcellulose (HPMC)	Binder and film former for drug layering
Ethyl Cellulose / Eudragit RS / Eudragit NE	Extended-release polymer for controlled 24-hour drug release
PEG 6000 / Triethyl Citrate	Plasticizer to improve flexibility and integrity of polymer coating
Talc / Colloidal Silicon Dioxide	Anti-adherent / Glidant to enhance flow properties during processing
Purified Water	Solvent (completely evaporated during processing)

Why Choose Pellets from Salius Pharma?

Salius Pharma offers Memantine Hydrochloride Extended Release (ER) Pellets manufactured in USFDA-approved, WHO-GMP, and ISO-certified facilities in India. Our process ensures full compliance with international regulatory standards and incorporates advanced pelletization and polymer coating technologies for optimal controlled drug release and enhanced bioavailability. Available in a range of customizable strengths and pellet sizes, these pellets are ideal for formulating once-daily oral therapies for Alzheimer’s disease.

Key Advantages of Partnering with Salius Pharma

Cost-Efficient Setup
Avoid heavy capital investment in infrastructure and workforce.
Guaranteed Quality Assurance
Products are sourced only from certified facilities with validated processes.
Access to Advanced Technology
Benefit from the latest drug delivery systems without managing the tech in-house.
Accelerated Market Entry
Launch products faster and establish your brand in less time.
Custom Formulation Support
Flexibility to offer tailored pellet solutions as per your market needs.

Expected Delivery Time

We ensure prompt and reliable shipping worldwide. Delivery times may vary depending on destination, order volume, and regulatory requirements.

Place an Order or Request a Quote from Salius Pharma

Looking to source Memantine HCl ER Pellets or other high-quality pharmaceutical pellet formulations?
Whether you need Active Pharmaceutical Ingredients (APIs), excipients, or regulatory support, our team is ready to provide reliable, compliant, and cost-effective solutions tailored to your market needs.

Get in Touch

Email: export@saliuspharma.com
Call / WhatsApp: +91 84258 80640 / +91 84258 80643
Landline: +91 22 49700 601 / +91 22 44503 148
Corporate Office: 3104–3106, Plan S Business Park, Nerul MIDC Opp. Dr. D.Y. Patil Stadium, Navi Mumbai – 400706, Maharashtra, India

Confidentiality Notice

The contents of this page and any attachments are intended solely for the designated recipient(s) and may contain confidential and/or privileged information protected by law.

Any patented products are excluded from our offerings in regions where such patents are currently in force.

FAQs

Memantine HCl ER Pellets are extended-release multiparticulate oral dosage forms designed to provide a controlled and consistent release of Memantine, improving therapeutic efficacy and patient adherence in neurological treatments.

Yes. These extended-release pellets can be directly filled into capsules, sachets, or multiparticulate formulations, providing manufacturers with versatile options for oral delivery.

Salius Pharma provides custom drug loads, pellet size, and coating materials to tailor the extended-release profile according to formulation needs or regulatory requirements.

All batches are manufactured under GMP conditions, tested for content uniformity, dissolution, and stability, and supplied with complete regulatory documentation (CoA, MSDS, stability reports) for safe export and compliance.

Enquiries for export only